

## Therapeutics Advisory Group Update - Issue 27 – January 2024

All recommendations discussed at the **January** TAG and D+TC meetings and ratified by the Planned Care and Medicines Management Working Group on behalf of the ICB – **January 2024**. Please share within your organisation as appropriate

### Commissioning Summary

|   |   |
|---|---|
| <p><b>Commissioning Review</b> - Off-label use of <b>Testosterone</b> in women for hypoactive sexual disorder during the menopause – <b>amendment to prescribing responsibility</b></p>   | <ul style="list-style-type: none"> <li>• <b>ADVICE – Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation.</b></li> <li>• Shared Care Agreement to be amended to Prescribing Guidance document</li> </ul>   |
| <p><b>Formulary Application - Brivaracetam</b> for partial-onset seizures in idiopathic generalised epilepsy</p>  | <ul style="list-style-type: none"> <li>• <b>ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation.</b></li> <li>• Prescription for the first month will be the responsibility of the neurology department.</li> <li>• GP will assume responsibility for writing and issuing subsequent prescriptions with any adjustments to the dose being on the advice of the neurologists and epilepsy specialist nurses</li> </ul> |
| <p><b>Formulary Application - Glycopyrronium bromide 2% in cetomacrogol cream</b> for craniofacial hyperhidrosis</p>  | <ul style="list-style-type: none"> <li>• <b>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</b></li> </ul>   |
| <p><b>Formulary Applications and Reviews:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">TA679</a> - <b>Dapagliflozin</b> for treating chronic heart failure with reduced ejection fraction – February 2021</li> <li>• <a href="#">TA773</a> - <b>Empagliflozin</b> for treating chronic heart failure with reduced ejection fraction – March 2022</li> <li>• <a href="#">TA902</a> - <b>Dapagliflozin</b> for treating chronic heart failure with preserved or mildly reduced ejection fraction – June 2023</li> <li>• <a href="#">TA929</a> - <b>Empagliflozin</b> for treating chronic heart failure with preserved or mildly reduced ejection fraction – November 2023</li> </ul> | <ul style="list-style-type: none"> <li>• <b>ADVICE - Primary care may initiate dapagliflozin / empagliflozin following specialist recommendation.</b></li> <li>• Existing shared care agreement for 'Dapagliflozin and Empagliflozin for chronic heart failure with reduced ejection fraction' will be amended to Prescribing Guidance document.</li> </ul>   |
| <p><b>Local Guidance</b> for information</p> <ul style="list-style-type: none"> <li>• Norfolk and Waveney <b>Antimicrobial Prescribing</b> Guidance</li> <li>• Guidance for the appropriate prescribing for <b>phenylketonuria (PKU)</b></li> <li>• <b>Bladder &amp; Bowel Continence</b> Product Formulary Prescribing Guide – 2023</li> <li>• <b>Stoma Fair Usage Policy</b> – December 2023</li> </ul>   |   |

## Shared Care Updates

- **Agreed following minor amendments:**
  - **Melatonin** for sleep disorders in children
  - **Hydroxycarbamide** for myeloproliferative disorders for patients within adult services
  - Use of **Azathioprine** in Ulcerative Colitis & Crohn's Disease

## **Feedback from formulary and clinical groups**

|   |  |
|---|--|
| • <b>Netformulary</b>                                     | • Skin section now live  |
| • <b>Knowledge Anglia / Knowledge NoW</b>                 | <ul style="list-style-type: none"> <li>• Knowledge Anglia closing soon</li> <li>• Knowledge NoW to be launched 3<sup>rd</sup> April 2024</li> <li>• External links to websites such as NICE and NHS England will be hosted on Netformulary</li> </ul>                      |
| • <b>Bimatoprost/Timolol eye drop</b>                     | <ul style="list-style-type: none"> <li>• New generic Bimatoprost/Timolol eye drop available which is more cost-effective.</li> <li>• Netformulary entry updated so that Ganfort® is no longer specified</li> </ul>   |
| • <b>Epimax Eyelid Ointment</b>                           | <ul style="list-style-type: none"> <li>• Available OTC.</li> <li>• Suggest <b>BLACK – Not commissioned. No prescribing in primary or secondary care classification</b> in line with the other eyelid ointments</li> </ul>  |
| • <b>Anticipatory Prescribing</b> in End of Life (Adults) | <ul style="list-style-type: none"> <li>• Updated Key Message bulletin</li> <li>• Amended to match the Ardens template</li> </ul>   |
| • <b>Sitagliptin</b> price drop                           | <ul style="list-style-type: none"> <li>• Sitagliptin <b>first choice</b> for new patients where clinically appropriate</li> <li>• Alogliptin patients will be reviewed to see if appropriate to switch</li> <li>• Netformulary updated and comms being prepared</li> </ul> |
| • <b>Apixaban</b> price drop                              | <ul style="list-style-type: none"> <li>• Apixaban price has reduced so this is now <b>first-line</b> option</li> <li>• For new patients/diagnosis of AF</li> <li>• Existing patients to remain on current treatment</li> </ul>   |
| • <b>Emulsifying ointment</b>                             | <ul style="list-style-type: none"> <li>• Emulsifess is the most cost-effective brand</li> <li>• Noted on Netformulary</li> </ul>   |

## NICE Guidance – acknowledged by the TAG

|   |
|---|
| <a href="#">CG98 – May 2010, updated October 2023</a> - Jaundice in newborn babies under 28 days  |
| <a href="#">CG191 – December 2014, updated October 2023</a> - Pneumonia in adults: diagnosis and management   |
| <a href="#">CG164 – June 2013, updated November 2023</a> - Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| <a href="#">NG237 – October 2023, updated November 2023</a> - Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management                              |
| <a href="#">NG136 – August 2019, updated November 2023</a> - Hypertension in adults: diagnosis and management   |
| <a href="#">CG109 – August 2010, updated November 2023</a> - Transient loss of consciousness ('blackouts') in over 16s  |
| <a href="#">NG191 – March 2021, updated November 2023</a> - COVID-19 rapid guideline: managing COVID-19   |
| <a href="#">NG198 – June 2021, updated December 2023</a> - Acne vulgaris: management  |
| <a href="#">NG238 – December 2023</a> - Cardiovascular disease: risk assessment and reduction, including lipid modification   |
| <a href="#">CG185 – September 2014, updated December 2023</a> - Bipolar disorder: assessment and management   |

### NICE Technology Appraisals – ICB Commissioning Responsibility

|   |  |
|---|--|
| <p><a href="#">TA274 – February 2013, updated October 2023</a> - Ranibizumab (Lucentis®) for treating diabetic macular oedema (and biosimilars) – <b>review found nothing new to change existing recommendations</b></p>  | <p><b>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</b></p>   |
| <p><a href="#">TA929 – November 2023</a> - Empagliflozin (Jardiance®) for treating chronic heart failure with preserved or mildly reduced ejection fraction (<b>30 day implementation</b>)</p>  | <p><b>ADVICE - Primary care clinician may initiate dapagliflozin / empagliflozin following specialist recommendation</b></p>   |
| <p><a href="#">TA942 – December 2023</a> - Empagliflozin (Jardiance®) for treating chronic kidney disease</p>   | <p><b>GREEN - can be initiated by prescriber in primary care</b></p>   |
| <p><a href="#">TA943 – December 2023</a> - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes</p> <p>NICE have agreed to a request from NHS England to allow a phased five-year implementation of this appraisal.</p> <p>They will also provide funding to reimburse 75% of ICB's estimated costs for hybrid closed-loop, based on regular reporting of local data</p> | <p><b>BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required</b></p> |
| <p><a href="#">TA937 – December 2023</a> - Targeted-release budesonide (Kinpeygo®) for treating primary IgA nephropathy</p>   |  |

### NICE Technology Appraisals – NHS England Commissioning Responsibility

|   |   |
|---|---|
| <p><a href="#">TA928 – November 2023</a> - Cabozantinib (Cabometyx®) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine</p>       | <p><b>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</b></p>                            |
| <p><a href="#">TA930 – November 2023</a> - Lutetium-177 vipivotide tetraxetan (Pluvicto®) for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments</p> |   |
| <p><a href="#">TA931 – November 2023</a> - Zanubrutinib (Brukinsa®) for treating chronic lymphocytic leukaemia</p>  | <p><b>RED/HOSPITAL - Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care</b></p> |
| <p><a href="#">TA934 – November 2023</a> - Foslevodopa–foscarbidopa (Produodopa®) for treating advanced Parkinson's with motor symptoms</p>   |   |
| <p><a href="#">TA935 – December 2023</a> - Secukinumab (Cosentyx®) for treating moderate to severe hidradenitis suppurativa</p>   |   |
| <p><a href="#">TA939 – December 2023</a> - Pembrolizumab (Keytruda®) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer</p>                  |   |
| <p><a href="#">TA755 – December 2021, updated December 2023</a> - Risdiplam (Evrysdi®) for treating spinal muscular atrophy</p>   |   |

## NICE Technology Appraisals – Terminated Appraisals

|  |  |
|--|--|
| <p><a href="#">TA932 – November 2023</a> - Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable</p>               | <p><b>BLACK - Not commissioned. No NHS prescribing in primary or secondary care. Not recommended by NICE</b></p> |
| <p><a href="#">TA933 – November 2023</a> - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies</p> |  |
| <p><a href="#">TA936 – November 2023</a> - Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments</p>               |  |
| <p><a href="#">TA938 – December 2023</a> - Dupilumab for treating eosinophilic oesophagitis in people 12 years and over</p>  |  |
| <p><a href="#">TA940 – December 2023</a> - Ravulizumab for treating generalised myasthenia gravis</p>  |  |
| <p><a href="#">TA941 – December 2023</a> - Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder</p>                                |  |

## NICE NHS England Highly Specialised Technologies

|  |  |
|--|--|
| <p><a href="#">HST29 – December 2023</a> - Velmanase alfa (Lamzede®) for treating alpha-mannosidosis</p> | <p><b>Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care</b></p> |
|--|--|

## Useful Information

|  |                                   |
|--|-----------------------------------|
| <b>Next meeting</b>                    | <b>Wednesday 6th March 2024</b>   |
| <b>Deadline for agenda submissions</b> | <b>Tuesday 27th February 2024</b> |